Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of alternative dose fingolimod for multiple sclerosis.
Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I. Longbrake EE, et al. Among authors: lathi e. Neurol Clin Pract. 2018 Apr;8(2):102-107. doi: 10.1212/CPJ.0000000000000434. Neurol Clin Pract. 2018. PMID: 29708225 Free PMC article.
A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis.
Money KM, Mahatoo A, Samaan S, Anand P, Baber U, Bailey M, Bakshi R, Bouley A, Bower A, Cahill J, Houtchens M, Katz J, Lathi E, Levit E, Longbrake EE, McAdams M, Napoli S, Raibagkar P, Wade P, Sloane JA. Money KM, et al. Among authors: lathi e. Neurol Neuroimmunol Neuroinflamm. 2021 Aug 2;8(5):e1046. doi: 10.1212/NXI.0000000000001046. Print 2021 Sep. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34341094 Free PMC article.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B, Medin J, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Silva D, Zivadinov R; MS-MRIUS Study Group. Weinstock-Guttman B, et al. Among authors: lathi e. CNS Drugs. 2018 Jan;32(1):75-84. doi: 10.1007/s40263-017-0482-4. CNS Drugs. 2018. PMID: 29270772 Free PMC article.
No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study.
Zivadinov R, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Kolodny S, Silva D, Medin J, Weinstock-Guttman B; MS-MRIUS study group. Zivadinov R, et al. Among authors: lathi e. Curr Med Res Opin. 2018 Aug;34(8):1431-1440. doi: 10.1080/03007995.2018.1458708. Epub 2018 Apr 12. Curr Med Res Opin. 2018. PMID: 29648900
Recommendations for cognitive screening and management in multiple sclerosis care.
Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, Gingold J, Goverover Y, Halper J, Harris C, Kostich L, Krupp L, Lathi E, LaRocca N, Thrower B, DeLuca J. Kalb R, et al. Among authors: lathi e. Mult Scler. 2018 Nov;24(13):1665-1680. doi: 10.1177/1352458518803785. Epub 2018 Oct 10. Mult Scler. 2018. PMID: 30303036 Free PMC article. Review.
28 results